Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
As of close of business last night, Arcturus Therapeutics Holdings Inc’s stock clocked out at $19.39, up 2.32% from its previous closing price of $18.95. In other words, the price has increased by $2.32 from its previous closing price. On the day, 0.6 million shares were traded. ARCT stock price reached its highest trading level at $19.805 during the session, while it also had its lowest trading level at $18.79.
Ratios:
To gain a deeper understanding of ARCT’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.90 and its Current Ratio is at 5.90. In the meantime, Its Debt-to-Equity ratio is 0.12 whereas as Long-Term Debt/Eq ratio is at 0.10.
On May 28, 2025, Scotiabank started tracking the stock assigning a Sector Outperform rating and target price of $32.
On January 28, 2025, BTIG Research started tracking the stock assigning a Buy rating and target price of $41.BTIG Research initiated its Buy rating on January 28, 2025, with a $41 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Oct 15 ’24 when Chivukula Pad sold 12,000 shares for $20.76 per share. The transaction valued at 249,121 led to the insider holds 435,334 shares of the business.
Chivukula Pad bought 12,000 shares of ARCT for $249,121 on Oct 15 ’24.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ARCT now has a Market Capitalization of 526526272 and an Enterprise Value of 357023328. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.80 while its Price-to-Book (P/B) ratio in mrq is 2.28. Its current Enterprise Value per Revenue stands at 2.923 whereas that against EBITDA is -5.155.
Stock Price History:
The Beta on a monthly basis for ARCT is 2.48, which has changed by -0.075345755 over the last 52 weeks, in comparison to a change of 0.1443547 over the same period for the S&P500. Over the past 52 weeks, ARCT has reached a high of $23.59, while it has fallen to a 52-week low of $8.04. The 50-Day Moving Average of the stock is 7.90%, while the 200-Day Moving Average is calculated to be 29.99%.
Shares Statistics:
It appears that ARCT traded 664.99K shares on average per day over the past three months and 994660 shares per day over the past ten days. A total of 27.15M shares are outstanding, with a floating share count of 24.86M. Insiders hold about 8.44% of the company’s shares, while institutions hold 95.20% stake in the company. Shares short for ARCT as of 1759190400 were 5143436 with a Short Ratio of 7.73, compared to 1756425600 on 5408973. Therefore, it implies a Short% of Shares Outstanding of 5143436 and a Short% of Float of 29.28.
Earnings Estimates
The market rating for Arcturus Therapeutics Holdings Inc (ARCT) is a result of the insights provided by 9.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is -$0.94, with high estimates of -$0.12 and low estimates of -$1.88.
Analysts are recommending an EPS of between -$1.04 and -$4.42 for the fiscal current year, implying an average EPS of -$2.53. EPS for the following year is -$2.06, with 9.0 analysts recommending between $1.41 and -$4.78.
Revenue Estimates
A total of 11 analysts have provided revenue estimates for ARCT’s current fiscal year. The highest revenue estimate was $116.18M, while the lowest revenue estimate was $57.68M, resulting in an average revenue estimate of $89.64M. In the same quarter a year ago, actual revenue was $152.31MBased on 11 analysts’ estimates, the company’s revenue will be $101.46M in the next fiscal year. The high estimate is $279.39M and the low estimate is $14.63M.
